The social networking site, Facebook, has gained an enormous amount of popularity. In this article, we review the literature on the factors contributing to Facebook use. We propose a model suggesting that Facebook use is motivated by two primary needs: (1) The need to belong and (2) the need for self-presentation. Demographic and cultural factors contribute to the need to belong, whereas neuroticism, narcissism, shyness, self-esteem and self-worth contribute to the need for self presentation. Areas for future research are discussed.

Facebook (FB) and Twitter are popular social networking sites. This study examined differences between those who use both sites versus only FB, to test the hypothesis that mono-users differ in their personality characteristics from users active in both websites. Participants were 205 undergraduate students; 96 only used FB, 109 used FB and Twitter. Participants who used both sites reported significantly lower loneliness, higher number of FB friends, and lower number of minutes spent online, as compared to those who only used FB. Loneliness was positively associated with FB use only in those who used FB alone, but was negatively associated with and negatively predicted both FB and Twitter use in those who used both websites. Findings suggest that more intense use of online interactions is more frequently found in mono-users (people using only Facebook) as compared to those using both websites, and it is predicted by increased feelings of loneliness. The current study findings provide additional insights on what personality factors may make some people prone to excessive use of social networking sites.

As the number of psychotropics on the market expands, the likelihood increases that a patient requiring anticoagulation with warfarin will receive concurrent treatment with a psychotropic drug. Because warfarin undergoes hepatic metabolism and is highly protein bound, it is particularly prone to drug interactions; in addition, its relatively narrow therapeutic window places patients at risk of either hemorrhagic or thrombotic complications. Although warfarin's interactions with other drugs have long been studied, the most recent review of the literature of warfarin's interactions with psychotropics was over a decade ago. Thus, we conducted a systematic review of the literature documenting the interaction between warfarin and psychotropics, with a focus on interactions mediated through the cytochrome P450 system and protein binding. A search of the MEDLINE database was performed, and reports of warfarin interactions with psychotropics were identified. The results suggest that interactions between warfarin and psychotropic drugs are important and likely underrecognized. They also have notable implications for both safety and drug compliance. When certain psychotropics are started or discontinued in patients receiving warfarin therapy, or when warfarin is introduced to a patient receiving a stable dose of a psychotropic, clinicians should monitor a patient's international normalized ratio (INR) closely to ensure it remains within therapeutic range. Psychotropics that pose a particular risk of increasing the INR when used with warfarin include fluoxetine, fluvoxamine, quetiapine, and valproic acid. Psychotropics that may significantly decrease the INR when used with warfarin include trazodone, St. John's wort, carbamazepine, and the polycyclic aromatic carbons in tobacco cigarettes; however, nicotine itself, as in nicotine replacement strategies, is not known to alter warfarin's anticoagulant effect. In certain cases, the need for anticoagulation may also necessitate switching to a different psychotropic.